An interventional study of ICE Treatment and TAI Standard-of-Care Treatment in Constipation Chronic Idiopathic, sponsored by usMIMA S.L.. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-22.
Sponsored by usMIMA S.L. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies in Constipation with a site in United Kingdom — 4 open to participants now, 5 under way, none of them phase 3. Constipation · United Kingdom.
Among the 61 studies in Constipation with a site in United Kingdom, this one is the 36th largest by planned enrollment of the 54 interventional ones that give a count, is one of 3 that started in 2025, is one of 23 with no phase, and was the 57th registered.
1,048 studies on the registry are indexed under Constipation; 161 are open to participants now.
Browse Constipation studies →4 of the 61 studies in Constipation with a site in United Kingdom are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United Kingdom, United States, Belgium and 5 more countries
Ages 18–75
University of Cambridge · Sites in United Kingdom
Ages 55+ · Healthy volunteers
University of Nottingham · Sites in United Kingdom
Ages 6+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 15 · Phase 4 6
First in 1998; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 75 across 886 interventional studies indexed under Constipation.
Median enrollment 93 across the 54 interventional studies, 170 across the 7 observational. Of the 50 that completed or were terminated, 16 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 61 have an industry lead sponsor. The 10 most frequent:
usMIMA S.L. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
usMIMA S.L. has 4 studies filed under Constipation — fewer than ten, so there is no comparison to draw.
2 of the studies in Constipation with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07786116University of CambridgeThe Role of METhanogens in the PROgression Of Parkinson's Disease and Related Neurological Conditions | 2027-06 |
| NCT07545772Eli Lilly and CompanyA Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C) | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 61 studies in Constipation with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective, open-labelled, longitudinal, controlled study aims to evaluate the suitability of Intermittent Colonic Exoperistalsis (ICE) treatment for adults with refractory chronic constipation who are awaiting trans-anal irrigation (TAI). The ICE treatment will be applied using the MOWOOT device (USMIMA). The study involves two treatment groups: an experimental group receiving daily ICE treatments and a control group following standard TAI care. Participants will serve as their own controls in pre- and post-treatment analyses to assess changes in bowel management satisfaction and other outcomes.
This study is a prospective, open-labelled, longitudinal, controlled trial conducted at a single center. It aims to assess the suitability of Intermittent Colonic Exoperistalsis (ICE) treatment for bowel management in adults with refractory chronic constipation who are awaiting trans-anal irrigation (TAI). The ICE treatment will be applied using the MOWOOT device (USMIMA). The study includes two treatment groups:
Experimental ICE Group: Participants will receive one ICE treatment session lasting 20 minutes daily, at the same hour, for 12 weeks.
Control TAI Group: Participants will follow the usual TAI standard-of-care treatment for 12 weeks.
Participants will be given the option to choose between the ICE treatment and the TAI treatment after both options are explained to them. Healthcare professionals will recommend the most suitable treatment based on individual patient needs, but the final decision will rest with the patients.
The primary objective is to evaluate the change in satisfaction with daily quality of life related to bowel management, measured by a Likert scale (Bothersome scale). Secondary objectives include assessing the efficacy of the ICE treatment on chronic constipation, both qualitatively and quantitatively, and evaluating the economic impact from the hospital's perspective.
Secondary outcomes will be measured through various patient-reported and health professional-reported metrics, including changes in quality of life (PAC-QOL), constipation symptoms (PAC-SYM), constipation severity (CCCS), time spent in bowel management and evacuation, use of other treatments, number of consultations and hospital admissions, productivity, acceptability and ease of use of the ICE treatment, reported problems, compliance, adherence, and persistence in treatment. Health professional outcomes will include time spent per visit, total time spent until independent use of MOWOOT, ease of patient management, and patient treatment preferences.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
A subject will not be eligible for inclusion in this study if any of the following criteria apply:
Disease phenotype exclusion criteria:
Device-related exclusion criteria:
Other medical conditions, medications and :
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Each patient will receive 1 ICE treatment of 20 minutes at least once per day, every day at the same hour, during the intervention period of 12 weeks.
Device: ICE Treatment
Each patient will follow the usual TAI standard-of-care treatment for the intervention period of 12 weeks.
Procedure: TAI Standard-of-Care Treatment
Each patient in the Experimental ICE Group will receive one Intermittent Colonic Exoperistalsis (ICE) treatment session lasting 20 minutes. These sessions will be conducted at least once per day, every day at the same hour, for a total duration of 12 weeks. The ICE treatment involves using the MOWOOT medical device designed to alleviate chronic constipation by stimulating colonic peristalsis.
Each patient in the Control TAI Group will follow the usual Trans-Anal Irrigation (TAI) standard-of-care treatment. This involves the regular use of TAI procedures as prescribed by healthcare professionals for the intervention period of 12 weeks. The TAI treatment is a well-established method for managing chronic constipation by mechanically clearing the bowel.
Change in Satisfaction with Daily Quality of Life Related to Bowel Management
Assessed by the Bothersome Scale (a Likert scale) where 0 is 'not at all' and 10 is 'a great deal,' with higher scores indicating a worse outcome
Time frame: 12 weeks
Changes in Quality of Life According to PAC-QOL Score
Assessed by the PAC-QOL (Patient Assessment of Constipation Quality of Life) scale, where higher scores indicate a worse quality of life.
Time frame: 12 weeks
Changes in Constipation Symptoms According to PAC-SYM Score
Measured using the PAC-SYM (Patient Assessment of Constipation Symptoms) scale, with higher scores reflecting more severe constipation symptoms
Time frame: 12 weeks
Changes in Constipation Severity According to CCCS
Evaluated by the CCCS (Constipation Clinical Severity Scale), where higher scores denote greater severity of constipation
Time frame: 12 weeks
Change in Time Spent in Bowel Management
Measured in minutes per day, data from bowel diaries.
Time frame: 12 weeks
Change in Time Spent in Evacuation
Measured in minutes per day, data from bowel diaries.
Time frame: 12 weeks
Change in Use of Other Treatments (e.g., Laxatives, Suppositories)
Data from patient surveys.
Time frame: 12 weeks
Change in Number of Consultations to Primary Care (GP, Nurse)
Data from patient surveys.
Time frame: 12 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Jul 2026, 13 months after the start.
Of 71 industry-sponsored interventional studies with no phase under Constipation, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's planned 13 months is above that.
Counting every sponsor, half of 316 studies reached it within 14 months; a quarter within 6 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
usMIMA S.L.